HILPDA and nonpapillary renal cell carcinoma: The identification of the HILPDA+ ccRCC1 subtype provides novel insights into the role of cuproptosis in the immunosuppressive TME of ccRCC, and suggest potential cuproptosis-targeted therapy strategies for future clinical applications.